185 related articles for article (PubMed ID: 34328687)
1. Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes.
Steinman JB; Salomao MA; Pajvani UB
Liver Int; 2021 Nov; 41(11):2534-2546. PubMed ID: 34328687
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of ductular reaction in non-alcoholic steatohepatitis.
Chen Y; Gao WK; Shu YY; Ye J
World J Gastroenterol; 2022 May; 28(19):2088-2099. PubMed ID: 35664038
[TBL] [Abstract][Full Text] [Related]
3. Perturbed liver gene zonation in a mouse model of non-alcoholic steatohepatitis.
Zhou Y; Zhao Y; Carbonaro M; Chen H; Germino M; Adler C; Ni M; Zhu YO; Kim SY; Altarejos J; Li Z; Burczynski ME; Glass DJ; Sleeman MW; Lee AH; Halasz G; Cheng X
Metabolism; 2024 May; 154():155830. PubMed ID: 38428673
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
[TBL] [Abstract][Full Text] [Related]
5. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
Hall Z; Bond NJ; Ashmore T; Sanders F; Ament Z; Wang X; Murray AJ; Bellafante E; Virtue S; Vidal-Puig A; Allison M; Davies SE; Koulman A; Vacca M; Griffin JL
Hepatology; 2017 Apr; 65(4):1165-1180. PubMed ID: 27863448
[TBL] [Abstract][Full Text] [Related]
6. Wnt/beta-catenin signaling and its modulators in nonalcoholic fatty liver diseases.
Shree Harini K; Ezhilarasan D
Hepatobiliary Pancreat Dis Int; 2023 Aug; 22(4):333-345. PubMed ID: 36448560
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems.
Soto-Gutierrez A; Gough A; Vernetti LA; Taylor DL; Monga SP
Exp Biol Med (Maywood); 2017 Oct; 242(16):1605-1616. PubMed ID: 28467181
[TBL] [Abstract][Full Text] [Related]
8. Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis.
Zhu C; Tabas I; Schwabe RF; Pajvani UB
Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):131-142. PubMed ID: 33051603
[TBL] [Abstract][Full Text] [Related]
9. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
10. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.
Wang X; Zheng Z; Caviglia JM; Corey KE; Herfel TM; Cai B; Masia R; Chung RT; Lefkowitch JH; Schwabe RF; Tabas I
Cell Metab; 2016 Dec; 24(6):848-862. PubMed ID: 28068223
[TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
14. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
15. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.
Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM
BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560
[TBL] [Abstract][Full Text] [Related]
16. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Bril F; Barb D; Lomonaco R; Lai J; Cusi K
J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
[TBL] [Abstract][Full Text] [Related]
17. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
18. A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD.
Ashworth WB; Davies NA; Bogle ID
PLoS Comput Biol; 2016 Sep; 12(9):e1005105. PubMed ID: 27632189
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
20. Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD.
Murphy WA; Diehl AM; Loop MS; Fu D; Guy CD; Abdelmalek MF; Karachaliou GS; Sjöstedt N; Neuhoff S; Honkakoski P; Brouwer KLR
Hepatol Commun; 2024 Mar; 8(3):. PubMed ID: 38381537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
